January 30, 2018 / 1:30 PM / a month ago

BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel

Jan 30 (Reuters) - Puma Biotechnology Inc:

* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN ISRAEL

* PUMA BIOTECHNOLOGY INC - CO, MEDISON PHARMA LTD ENTERED INTO EXCLUSIVE AGREEMENT UNDER WHICH MEDISON WILL COMMERCIALIZE NERLYNX IN ISRAEL

* PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT, MILESTONE PAYMENTS THROUGHOUT AGREEMENT TERM, & DOUBLE DIGIT ROYALTIES ON NERLYNX SALES IN ISRAEL

* PUMA BIOTECHNOLOGY SAYS EXPECT TO RECEIVE REGULATORY APPROVAL FOR NERLYNX IN ISRAEL DURING H1 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below